The Scar Treatment Market, estimated at USD 13,122.2 Mn in 2025, is expected to exhibit a CAGR of 4.48% and reach USD 17,833.6 Mn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
The key players in the market are focusing on the adoption of inorganic growth strategies, such as partnerships and collaborations, in order to strengthen their market presence in the global scar treatment market, which is expected to drive the market growth over the forecast period. For instance, in March 2025, Alliance Pharma PLC, a leading international healthcare business, had bought a brand ScarAway from Perrigo Company plc, a registered manufacturer of private label over-the-counter pharmaceuticals, which will accelerate Alliance's strategy in the U.S.
Global Scar Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), that first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the global economies, social behaviors, and healthcare of every country in the world.
The COVID-19 pandemic affected the global economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regards to the transportation of drugs from one place to another.
The COVID-19 had a negative impact on the global scar treatment market, owing to the decreased number of surgical operations carried out in the COVID-19-pandemic. For instance, in August 2025, a study by Massachusetts General Hospital, which is a healthcare provider, has found that reductions in many types of surgical procedures precipitated by SARS-CoV-2 have not fully recovered to their pre-pandemic levels, resulting in severe backlogs and deferred surgeries that could have serious health care and cost implications for the future. Due to reduced number of surgeries, there is a decrease in the number of scar treatments.
Global Scar Treatment Market: Key Developments
In December 2025, Perrigo Company plc, a manufacturer of private label over-the-counter pharmaceuticals announced that it is ready to acquire HRA Pharma, a fast-growing consumer healthcare company. HRA is a star asset that will bring Perrigo a portfolio of market-leading over the counter self-care brands in growing categories, including blister care, women’s health and scar treatment.
In April 2025, GSK plc., one of the world's largest research-based pharmaceutical company, announced the acquisition of Sierra Oncology, Inc., a late-stage biopharmaceutical company, which will help to address the critical unmet medical needs of myelofibrosis patients with anemia.